1. What is it?
Bremelanotide is a synthetic peptide: a short chain of amino acids made as a medicinal substance. PT-141 is its earlier research designation. Vyleesi is the brand name of a medicine containing it. The names are related, but describe different levels of information: the molecule's name alone does not establish a particular product's quality, composition or status. Clinical publications concern a specific study product, not any vial bearing a similar label. [109] [111]
2. Why do people turn to it?
Interest in bremelanotide mainly concerns low libido, or desire for sex. Approval trials studied a specific condition: HSDD, persistent low sexual desire accompanied by significant distress. Acquired means the problem was not present before; generalized means it is not limited to a particular partner or situation. Participants were premenopausal women. Diagnosis requires considering health, medicines and relationships, because not every decrease in desire is this disorder. [109] [110]
3. How does it work?
The molecule stimulates melanocortin receptors, which are sites where cells receive certain signals. The effect on desire that interests researchers mainly involves the nervous system. However, the exact mechanism of improvement in HSDD symptoms has not been fully explained. This should not be equated with simply increasing blood flow to the genitals. Desire, arousal and sexual satisfaction are related but distinct experiences; improvement in one does not guarantee improvement in the others. [109] [111]
4. What do studies actually show?
The two RECONNECT trials randomly assigned a total of 1,267 women to treatment. The main follow-up period lasted 24 weeks. Researchers primarily assessed reported desire and distress related to low desire using established questionnaires. Results indicated improvement in both areas. However, this was not a test of sexual performance or a study of everyone with low libido. The findings apply to women who met detailed eligibility criteria. [110]
5. What do we still not know?
A total of 684 women entered the open-label study extension, and 272 completed it. The planned additional follow-up was 52 weeks. This design helps identify problems during longer treatment, but is vulnerable to selection: people who are willing and able to continue remain in the study. Participants also knew which medicine they were receiving. Sustained improvement should therefore not be presented as a guaranteed effect for every future patient. [111]
6. What are the risks?
Nausea, flushing and headache were commonly reported. Skin darkening, a temporary rise in blood pressure and a slower heart rate are also possible. Vyleesi is contraindicated in uncontrolled hypertension and known cardiovascular disease. Safety assessment also covers pregnancy and other medicines, because bremelanotide can alter the absorption of some oral products. Good tolerance in one person does not predict the response of another with a different health condition. [109] [111]
7. Is it an approved medicine?
Vyleesi has a US-approved indication for the described group of premenopausal women. Current product information does not include men, postmenopausal women or improving sexual performance. US approval is not EU marketing authorization. Bremelanotide should therefore not simply be described as approved in Europe. Status and legal availability must be assessed for the particular country and product. [109]
8. What is new in research?
Status checked on 3 November 2026: the current Vyleesi information record in DailyMed was updated on 13 November 2025. This does not automatically mean a new indication, and the main limitations on its use remain recorded. The key RECONNECT trials and their extension date from 2019, so we do not present them as a new discovery. The main question for readers remains whether the findings apply to their situation, rather than how popular the name PT-141 is. [109] [110] [111]
Where does this information come from?
References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.
Show sources and how they were checked
- VYLEESI- bremelanotide injection
Approved US prescribing information in DailyMed; record updated 13 November 2025, prescribing text revised March 2024; indications, limitations, contraindications, warnings and mechanism reviewed. Accessed: 3 November 2026.
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Two randomised phase 3 human trials; 2019, November issue; full PubMed abstract read · DOI: 10.1097/AOG.0000000000003500. Accessed: 03.11.2026.
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
Open-label extension of human trials; online 10 October 2019; full-text abstract, methods, results and limitations reviewed · DOI: 10.1097/AOG.0000000000003514. Accessed: 3 November 2026.